Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD

Inclusion Criteria: * Adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel * Symptomatic with regard to dyspnea (NYHA II-III, mMRC Dyspnea score \> 1) * Diagnosis of COPD (FEV1/FVC ratio \<70%, FEV1 \< 80%) * Patients with hyperinflation at rest defined as Residual Volume (RV) \> 135 % predicted * Diagnosis of moderate symptomatic ischaemic Congestive heart failure (LVEF \> 35 -45%) * Stability of CHF during the preceding 3 months (no hospitalization due to CHF, stable CHF medication) * Male or female aged \> 18 years * Written informed consent prior to study participation * The subject is willing and able to follow the procedures outlined in the protocol Exclusion Criteria: * Lack of informed consent * Pregnant and lactating females * Acute moderate-severe exacerbation of COPD, acute respiratory failure (pH \< 7,35 and/ or respiratory rate \> 30/min within 3 months prior to inclusion) * Unstable heart failure or planned change in medication (hospitalization due to CHF within 3 months prior to inclusion), any angina pectoris * Not symptomatic * Patient has been committed to an institution by legal or regulatory order * Participation in a parallel interventional clinical trial * Any COPD maintenance therapy before start of randomization * History or diagnosis of Asthma * LVEF \<35 % or ICD or pacemaker * Myocardial infarction 6 months prior inclusion * History of life-threatening arrhythmias (e.g. NSVT or ventricular tachycardia, aFib, AV-Block, pacemaker treatment etc.) * History of diagnosis of Thyrotoxicosis * Chronic kidney disease with an crea-clearance ≤30 ml/min * History of significant alcohol or drug abuse, as judged by the Investigator * Fibrotic lung disease (e.g. IPF, ILD) * Contraindications for MRT (e.g. pacemaker, defibrillator, ferromagnetic metal implants, tattoos, claustrophobia, etc. according to MRI checklist used in the clinical routine)